Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response

J. Roelands, W. Hendrickx, G. Zoppoli, R. Mall, M. Saad, K. Halliwill, G. Curigliano, D. Rinchai, J. Decock, L.G. Delogu, T. Turan, J. Samayoa, L. Chouchane, A. Ballestrero, E. Wang, P. Finetti, F. Bertucci, L.D. Miller, J. Galon, F.M. MarincolaP.J.K. Kuppen, M. Ceccarelli, D. Bedognetti

Research output: Contribution to journalArticlepeer-review


BACKGROUND: An immune active cancer phenotype typified by a T helper 1 (Th-1) immune response has been associated with increased responsiveness to immunotherapy and favorable prognosis in some but not all cancer types. The reason of this differential prognostic connotation remains unknown. METHODS: To explore the contextual prognostic value of cancer immune phenotypes, we applied a multimodal pan-cancer analysis among 31 different histologies (9282 patients), encompassing immune and oncogenic transcriptomic analysis, mutational and neoantigen load and copy number variations. RESULTS: We demonstrated that the favorable prognostic connotation conferred by the presence of a Th-1 immune response was abolished in tumors displaying specific tumor-cell intrinsic attributes such as high transforming growth factor-beta (TGF-β) signaling and low proliferation capacity. This observation was independent of mutation rate. We validated this observation in the context of immune checkpoint inhibition. WNT-β catenin, barrier molecules, Notch, hedgehog, mismatch repair, telomerase activity and AMPK signaling were the pathways most coherently associated with an immune silent phenotype together with mutations of driver genes including IDH1/2, FOXA2, HDAC3, PSIP1, MAP3K1, KRAS, NRAS, EGFR, FGFR3, WNT5A and IRF7. CONCLUSIONS: This is the first systematic study demonstrating that the prognostic and predictive role of a bona fide favorable intratumoral immune response is dependent on the disposition of specific oncogenic pathways. This information could be used to refine stratification algorithms and prioritize hierarchically relevant targets for combination therapies. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Original languageEnglish
Pages (from-to)e000617
JournalJ Immunother Cancer
Issue number1
Publication statusPublished - 2020


  • RIS


Dive into the research topics of 'Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response'. Together they form a unique fingerprint.

Cite this